CIBACEN

This brand name is authorized in Germany, Spain, Italy, Japan, Netherlands, Turkey

Active ingredients

The drug CIBACEN contains one active pharmaceutical ingredient (API):

1 Benazepril UNII N1SN99T69T - BENAZEPRIL HYDROCHLORIDE

Benazepril is a prodrug which, after hydrolysis to the active substance benazeprilat, inhibits the angiotensin-converting enzyme (ACE) and so blocks the conversion of angiotensin I to angiotensin II. This reduces all the effects mediated by angiotensin II – i.e. vasoconstriction and production of aldosterone, which promotes the reabsorption of sodium and water in the renal tubules – and elevates cardiac output. Read about Benazepril

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA07	Benazepril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 04511447, 04511476, 04511482, 04511507, 04511513, 04511542
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 59551, 59552, 59553
Country: IT	Agenzia del Farmaco	Identifier(s): 027516020, 027516032
Country: JP	医薬品医療機器総合機構	Identifier(s): 2144007F1027, 2144007F2023, 2144007F3020
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 36218
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8698856090065